Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1020 of 6351
-
Could your own fat cells heal Crohn's fistulas? new trial tests it
Disease control OngoingThis is a phase III study to evaluate the efficacy and safety of ASC(Autologous Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.
Phase 3 • Sponsor: Anterogen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for kidney cancer patients after immunotherapy fails
Disease control CompletedThe overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipil…
Phase 2 • Sponsor: Ipsen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Blood test may pinpoint cause of stunted fetal growth
Diagnosis CompletedThe main aim of this project is to determine the Placental Growth Factor and Vascular Endothelial Growth Factor ratio's performance (sFlt-1/PlGF) for the etiological diagnosis of vascular Intrauterine growth restriction (IUGR) compared to a non-vascular IUGR.
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Hope for rare liver disease: drug aims to ease severe itching in children
Disease control CompletedThe primary objective of this open label extension study is to evaluate the long-term safety and tolerability of maralixibat.
Phase 3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for hard-to-treat lung cancer: experimental drug targets MET gene
Disease control Recruiting nowThis study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determi…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for rare fat disorder
Disease control CompletedThe primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on fasting triglyceride levels in the subset of patients w…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can painting and clay ease the toll of chemotherapy?
Symptom relief CompletedThe purpose of this study is to evaluate the impact of art-therapeutic management on a patient with cancer, during chemotherapy treatment, on the reduction of physical or psychological symptoms. Art therapy is a non-drug approach that can help some patients cope with the consequ…
Sponsor: Centre Hospitalier de Perigueux • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
New drug tavapadon tested to ease Parkinson's symptoms
Disease control CompletedThe purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug combo shows promise for aggressive lymphoma patients
Disease control CompletedThis is a prospective single-arm, multi-center, phase II clinical trial to observe the efficacy and safety of R-CHOP (Rituximab-Cyclophosphamide, Epirubicin, Vincristine and Prednisone) combined with lenalidomide in the first-line treatment for patients with medium to high risk/h…
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New gene therapy targets Parkinson's in patients with specific gene flaw
Disease control OngoingStudy J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose lev…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug duo shows promise against tough uterine cancer
Disease control OngoingThis research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: * mirvetuximab soravtansine (IMGN853) * pembrolizumab
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Parkinson's fall risk could be cut in half by common memory drug
Disease control CompletedParkinson's disease is a common condition particularly affecting older people. Falls are a very frequent complication of the disease affecting 60% of people with Parkinson's every year. As the population ages, the number of people living with Parkinson's disease and the occurrenc…
Phase 3 • Sponsor: University of Bristol • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Artificial intelligence could help guide liver cancer treatment after surgery
Knowledge-focused CompletedThis is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC). We collected anonymized historical clinical data, preoperative gadoxetic acid-enhanced MRI scans and digital pathol…
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Can we predict which heart blockages will worsen after stenting?
Knowledge-focused OngoingThe goal of this observational study is to explore the risk factors and prognostic value of non-target coronary lesion progression in patients aged 18-80 years with established coronary artery disease who are scheduled for repeat coronary angiography. The main questions it aims t…
Sponsor: Beijing Anzhen Hospital • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a berry extract tame type 1 diabetes?
Disease control CompletedType 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing β-cells by autoreactive T cells. Sea buckthorn (SBT), a traditional Chinese medicine homologous to food, confers beneficial effects on the autoimmune system. Whether SBT regulates…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Immunotherapy after surgery may keep melanoma from coming back
Disease control OngoingSubjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time …
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Blood test could spot returning colon cancer months before scans
Knowledge-focused OngoingIMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance. The hypothesis of this study is that ctDNA guided post-operative surveillance combining ctDNA and radiological assessments c…
Sponsor: Claus Lindbjerg Andersen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
AI reads endoscopy images to spot dangerous esophageal tumors
Diagnosis OngoingThe goal of this retrospective observational study is to evaluate whether preoperative endoscopic imaging can accurately assess tumor invasion depth in patients with early esophageal neoplasia undergoing endoscopic submucosal dissection (ESD). The main question it aims to answer…
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New online program aims to lift the cloud of depression for new mothers
Symptom relief Recruiting nowIMPRINT strengthens maternal and child health by screening, treating and preventing maternal perinatal depression, the most common complication of pregnancy and the child's first 1000 days. It is associated with poor pregnancy outcome and perinatal mortality and has adverse conse…
Sponsor: Katri Räikkönen • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
AI reads CT scans to predict stomach Cancer's return
Knowledge-focused By invitation onlyThis study aims to develop a model for predicting postoperative recurrence in patients with LAGC using artificial intelligence (AI) technology based on preoperative computed tomography (CT) images
Sponsor: Liu Yang • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC